Lausanne biotech firm AC Immune has received a milestone from Genentech as part of its collaboration agreement for the treatment of Alzheimer’s disease.
AC Immune SA announced this week that it has received a milestone from Genentech as part of its collaboration agreement. Financial details were not disclosed. The Lausanne-based biopharmaceutical company focuses on neurodegenerative diseases and makes anti-Tau antibodies for the treatment of Alzheimer’s disease, among others.
The milestone marks Genentech’s selection of a lead antibody development candidate to develop further towards clinical trials. Alzheimer’s is one of the biggest healthcare problems of the age and AC Immune and Genentech, which is a member of the Roche Group, will continue to work together on further development candidates.
Under the terms of the licensing agreement, AC Immune received an undisclosed upfront payment and is eligible to receive research, development and commercialisation milestone payments of more than CHF400 million. Additionally, it also receives royalties on net sales of products resulting from the collaboration. Genentech has global responsibility for pre-clinical and clinical development, manufacturing and commercialisation of products resulting from the collaboration.
Please login or sign up to comment.
Commenting guidelines